Inventor · disambiguated record
Paul Ridker
Also filed as: RIDKER PAUL · RIDKER PAUL M
10 granted patents·11 pending applications·297 citations·filing 1998–2023
89Inventor score
Files withBRIGHAM & WOMENS HOSPITAL8NOVARTIS AG5BRIGHAM & WOMENS HOSPITAL INC3CELERA CORP2RIDKER PAUL M2
Top patents by PatentIndex Score
21 records- 0194US6040147ASystemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic diseaseBRIGHAM & WOMENS HOSPITAL·Filed 1998·Granted Mar 21, 2000·236 cites·47 claims
- 0289US7964614B2Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic diseaseBRIGHAM & WOMENS HOSPITAL·Filed 2005·Granted Jun 21, 2011·8 cites·12 claims
- 0386US7943317B2Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatmentBRIGHAM & WOMENS HOSPITAL·Filed 2008·Granted May 17, 2011·7 cites·21 claims
- 0481US10550433B2Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatmentBRIGHAM & WOMENS HOSPITAL INC·Filed 2017·Granted Feb 4, 2020·2 cites·5 claims
- 0581US9164104B2Relevance of achieved levels of markers of systemic inflammation following treatmentRIDKER PAUL M·Filed 2005·Granted Oct 20, 2015·3 cites·28 claims
- 0678US11697850B2Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatmentCELERA CORP·Filed 2019·Granted Jul 11, 2023·0 cites·16 claims
- 0778US7189518B2Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseasesBRIGHAM & WOMENS HOSPITAL·Filed 2002·Granted Mar 13, 2007·21 cites·10 claims
- 0873US2024043525A1Use of canakinumabNOVARTIS AG·Filed 2023·Application pending·0 cites
- 0971US2022389090A1Use of il-1beta binding antibodiesNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1064US2015284799A1Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatmentBRIGHAM & WOMENS HOSPITAL·Filed 2014·Application pending·0 cites
- 1162US2023220063A1Il-1beta binding antibodies for use in treating cancerNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1261US2019048072A1USE OF IL-1beta BINDING ANTIBODIESNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1360US7030152B1Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic diseaseBRIGHAM & WOMENS HOSPITAL·Filed 1999·Granted Apr 18, 2006·20 cites·6 claims
- 1460US2014024623A1Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatmentCELERA CORP·Filed 2013·Application pending·0 cites
- 1557US2020239564A1Use of canakinumabNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1656US11435363B2Relevance of achieved levels of markers of systemic inflammation following treatmentBRIGHAM & WOMENS HOSPITAL INC·Filed 2015·Granted Sep 6, 2022·0 cites·12 claims
- 1756US2011206667A1Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatmentBRIGHAM & WOMENS HOSPITAL·Filed 2011·Application pending·0 cites
- 1852US2004235942A1Method for preventing recurring venous thromboembolism using long-term low-intensity warfarinFiled 2004·Application pending·0 cites
- 1951US2021324067A9Combination therapy for cardiovascular diseasesBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Application pending·0 cites
- 2048US2008058360A1Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseasesBRIGHAM & WOMENS HOSPITAL·Filed 2007·Application pending·0 cites
- 2133US8101363B2Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetesRIDKER PAUL M·Filed 2001·Granted Jan 24, 2012·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Paul Ridker files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →